Adaptive Biotechnologies (FRA:1HM) Cash Flow for Lease Financing : €0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Cash Flow for Lease Financing?

Adaptive Biotechnologies's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was €0.0 Mil. Adaptive Biotechnologies's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Dec. 2023 ), Adaptive Biotechnologies's Cash Flow for Lease Financing remained the same in Mar. 2024 (€0.0 Mil).

Adaptive Biotechnologies Cash Flow for Lease Financing Historical Data

The historical data trend for Adaptive Biotechnologies's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Cash Flow for Lease Financing Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow for Lease Financing

Get a 7-Day Free Trial

Adaptive Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow for Lease Financing	Get a 7-Day Free Trial															-	-	-	-	-

Adaptive Biotechnologies Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Adaptive Biotechnologies Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (FRA:1HM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

ADPT:USA 1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines